Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 DNA Hypomethylating Drugs in Cancer Therapy.

Literature DB >> 28159832

DNA Hypomethylating Drugs in Cancer Therapy.

Takahiro Sato¹, Jean-Pierre J Issa^1,2, Patricia Kropf².

Abstract

Aberrant DNA methylation is a critically important modification in cancer cells, which, through promoter and enhancer DNA methylation changes, use this mechanism to activate oncogenes and silence of tumor-suppressor genes. Targeting DNA methylation in cancer using DNA hypomethylating drugs reprograms tumor cells to a more normal-like state by affecting multiple pathways, and also sensitizes these cells to chemotherapy and immunotherapy. The first generation hypomethylating drugs azacitidine and decitabine are routinely used for the treatment of myeloid leukemias and a next-generation drug (guadecitabine) is currently in clinical trials. This review will summarize preclinical and clinical data on DNA hypomethylating drugs as a cancer therapy.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28159832 PMCID： PMC5411681 DOI： 10.1101/cshperspect.a026948

Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN： 2157-1422 Impact factor: 6.915

123 in total

1. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation.

Authors: Yutaka Kondo; Lanlan Shen; Pearlly S Yan; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal: Proc Natl Acad Sci U S A Date: 2004-05-03 Impact factor: 11.205

2. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.

Authors: A R Karpf; P W Peterson; J T Rawlins; B K Dalley; Q Yang; H Albertsen; D A Jones
Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205

3. Methylation and silencing of the Thrombospondin-1 promoter in human cancer.

Authors: Q Li; N Ahuja; P C Burger; J P Issa
Journal: Oncogene Date: 1999-05-27 Impact factor: 9.867

4. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

Authors: Jean-Pierre J Issa; Vazganush Gharibyan; Jorge Cortes; Jaroslav Jelinek; Gail Morris; Srdan Verstovsek; Moshe Talpaz; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal: J Clin Oncol Date: 2005-05-09 Impact factor: 44.544

5. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Authors: Melissa J Peart; Gordon K Smyth; Ryan K van Laar; David D Bowtell; Victoria M Richon; Paul A Marks; Andrew J Holloway; Ricky W Johnstone
Journal: Proc Natl Acad Sci U S A Date: 2005-02-28 Impact factor: 11.205

6. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544

7. CpG island methylator phenotype in colorectal cancer.

Authors: M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal: Proc Natl Acad Sci U S A Date: 1999-07-20 Impact factor: 11.205

8. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Authors: P Wijermans; M Lübbert; G Verhoef; A Bosly; C Ravoet; M Andre; A Ferrant
Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544

9. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.

Authors: L Zhou; X Cheng; B A Connolly; M J Dickman; P J Hurd; D P Hornby
Journal: J Mol Biol Date: 2002-08-23 Impact factor: 5.469

10. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors: Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal: Blood Date: 2003-11-06 Impact factor: 22.113

46 in total

Review 1. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Authors: Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal: Cold Spring Harb Perspect Med Date: 2019-04-01 Impact factor: 6.915

2. Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia.

Authors: Michael R McKeown; Liv Johannessen; Emily Lee; Christopher Fiore; Emmanuelle di Tomaso
Journal: Haematologica Date: 2018-10-18 Impact factor: 9.941

3. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.

Authors: Yongsuk Ku; Joo-Hwan Park; Ryeongeun Cho; Yongki Lee; Hyoung-Min Park; MinA Kim; Kyunghoon Hur; Soo Young Byun; Jun Liu; Young-Suk Lee; David Shum; Dong-Yeop Shin; Youngil Koh; Je-Yoel Cho; Sung-Soo Yoon; Junshik Hong; Yoosik Kim
Journal: Proc Natl Acad Sci U S A Date: 2021-03-30 Impact factor: 11.205

DNA Hypomethylating Drugs in Cancer Therapy.

1. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation.

2. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.

3. Methylation and silencing of the Thrombospondin-1 promoter in human cancer.

4. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

5. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

6. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

7. CpG island methylator phenotype in colorectal cancer.

8. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

9. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.

10. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Review 1. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

2. Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia.

3. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.

4. Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.

Review 5. Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types.

Review 6. Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity.

Review 7. Epigenetic Dysregulation of Myeloproliferative Neoplasms.

Review 8. Platinum Complexes in Colorectal Cancer and Other Solid Tumors.

Review 9. Ancient Adversary - HERV-K (HML-2) in Cancer.

Review 10. Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review.